The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | Key practical considerations for patients with solid tumor cancer and CHIP
Mrinal Patnaik, MBBS, Mayo Clinic, Rochester, MN, comments on the impact of clonal hematopoiesis of indeterminate potential (CHIP) on patients with solid tumors, emphasizing how the presence of CHIP may impact treatment and the risk of developing hematologic cancers. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think the most important point is how does the presence of CHIP impact the treatment that they’re going to receive, number one. Number two, how does the treatment interplay with this mutation in terms of their response to the therapy for the solid tumor, but also what does it do in terms of increasing their risk for developing either hematopoietic dysfunction or blood cancers. So to give you an example, if a patient comes in with a solid tumor and we detect CHIP in a gene, for example, TP53, we have to carefully weigh what type of treatment they’re getting for the solid tumor because it may allow the P53 clone to grow...
I think the most important point is how does the presence of CHIP impact the treatment that they’re going to receive, number one. Number two, how does the treatment interplay with this mutation in terms of their response to the therapy for the solid tumor, but also what does it do in terms of increasing their risk for developing either hematopoietic dysfunction or blood cancers. So to give you an example, if a patient comes in with a solid tumor and we detect CHIP in a gene, for example, TP53, we have to carefully weigh what type of treatment they’re getting for the solid tumor because it may allow the P53 clone to grow. It may cause impairment in how much dose of the drug they can get. It can cause cytopenias, which is low blood counts. But what we’ve observed in some of these patients in short duration, so less than two years, patients are developing MDS and AML, which is often not treatable in them because of how high grade it is.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
